VAX-NK is under clinical development by VaxCell Biotherapeutics and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VAX-NK’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VAX-NK overview
VAX-NK is under development for the treatment of hepatocellular carcinoma and extensive stage small cell lung cancer. It comprises of autologous natural killer (NK) cells and administered through parenteral route.
VaxCell Biotherapeutics overview
VaxCell Biotherapeutics (VaxcellBio) discovers and develops cell-based and protein-based immunotherapeutics for the treatment of cancer. The company’s pipeline products include Vax-CARs, Vaxleukin-15, Vax-DC/MM, a dendritic cell that enhances the mobility of lymph nodes and induces Th1 immune response in cancer cells, Vax-NK/HCC, a natural killer cell that inhibits metastasis, tumorigenesis and has a cytotoxic effect on malignant cells. It also investigates Vaxleukin 15, an anti-cancer immunotherapeutic indicated for canine companions. The company is investigating Vaxleukin candidates based on advanced genomics and recombinant protein engineering technology. VaxcellBio is headquartered in Hwasun, Jeollanam, South Korea.
For a complete picture of VAX-NK’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
